vs
LCNB CORP（LCNB）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是LCNB CORP的1.5倍（$35.5M vs $23.9M），LCNB CORP净利率更高（23.7% vs -304.2%，领先328.0%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 5.1%），LCNB CORP自由现金流更多（$33.4M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 15.7%）
LCNB集团是总部位于美国的金融控股公司，通过旗下附属国民银行开展业务，主要为俄亥俄州区域市场的个人消费者、中小企业及本地社区机构提供零售与商业银行产品、财富管理及保险相关服务。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
LCNB vs RXRX — 直观对比
营收规模更大
RXRX
是对方的1.5倍
$23.9M
营收增速更快
RXRX
高出676.6%
5.1%
净利率更高
LCNB
高出328.0%
-304.2%
自由现金流更多
LCNB
多$80.8M
$-47.3M
两年增速更快
RXRX
近两年复合增速
15.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $23.9M | $35.5M |
| 净利润 | $5.7M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 29.2% | -304.8% |
| 净利率 | 23.7% | -304.2% |
| 营收同比 | 5.1% | 681.7% |
| 净利润同比 | -7.6% | 39.6% |
| 每股收益（稀释后） | $0.40 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LCNBRXRX
| Q4 25 | $23.9M | $35.5M | ||
| Q3 25 | $23.8M | $5.2M | ||
| Q2 25 | $22.8M | $19.2M | ||
| Q1 25 | $21.5M | $14.7M | ||
| Q4 24 | $22.7M | $4.5M | ||
| Q3 24 | $21.4M | $26.1M | ||
| Q2 24 | $19.3M | $14.4M | ||
| Q1 24 | $17.8M | $13.8M |
净利润LCNBRXRX
| Q4 25 | $5.7M | $-108.1M | ||
| Q3 25 | $6.9M | $-162.3M | ||
| Q2 25 | $5.9M | $-171.9M | ||
| Q1 25 | $4.6M | $-202.5M | ||
| Q4 24 | $6.1M | $-178.9M | ||
| Q3 24 | $4.5M | $-95.8M | ||
| Q2 24 | $925.0K | $-97.5M | ||
| Q1 24 | $1.9M | $-91.4M |
毛利率LCNBRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率LCNBRXRX
| Q4 25 | 29.2% | -304.8% | ||
| Q3 25 | 35.6% | -3327.6% | ||
| Q2 25 | 31.6% | -916.8% | ||
| Q1 25 | 25.6% | -1297.9% | ||
| Q4 24 | 32.9% | -4042.4% | ||
| Q3 24 | 24.9% | -377.1% | ||
| Q2 24 | 4.9% | -697.4% | ||
| Q1 24 | 12.5% | -698.4% |
净利率LCNBRXRX
| Q4 25 | 23.7% | -304.2% | ||
| Q3 25 | 29.1% | -3135.3% | ||
| Q2 25 | 26.0% | -894.2% | ||
| Q1 25 | 21.4% | -1373.3% | ||
| Q4 24 | 27.0% | -3935.5% | ||
| Q3 24 | 21.2% | -367.5% | ||
| Q2 24 | 4.8% | -676.6% | ||
| Q1 24 | 10.7% | -662.4% |
每股收益（稀释后）LCNBRXRX
| Q4 25 | $0.40 | $-0.17 | ||
| Q3 25 | $0.49 | $-0.36 | ||
| Q2 25 | $0.41 | $-0.41 | ||
| Q1 25 | $0.33 | $-0.50 | ||
| Q4 24 | $0.44 | $-0.56 | ||
| Q3 24 | $0.31 | $-0.34 | ||
| Q2 24 | $0.07 | $-0.40 | ||
| Q1 24 | $0.15 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $21.6M | $743.3M |
| 总债务越低越好 | $104.4M | $9.6M |
| 股东权益账面价值 | $273.9M | $1.1B |
| 总资产 | $2.2B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.38× | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资LCNBRXRX
| Q4 25 | $21.6M | $743.3M | ||
| Q3 25 | $35.9M | $659.8M | ||
| Q2 25 | $49.8M | $525.1M | ||
| Q1 25 | $37.7M | $500.5M | ||
| Q4 24 | $35.7M | $594.4M | ||
| Q3 24 | $39.4M | $427.6M | ||
| Q2 24 | $34.9M | $474.3M | ||
| Q1 24 | $33.0M | $296.3M |
总债务LCNBRXRX
| Q4 25 | $104.4M | $9.6M | ||
| Q3 25 | $104.7M | $11.9M | ||
| Q2 25 | $105.0M | $14.2M | ||
| Q1 25 | $104.6M | $16.4M | ||
| Q4 24 | $155.2M | $19.0M | ||
| Q3 24 | $155.7M | $20.5M | ||
| Q2 24 | $162.2M | $22.9M | ||
| Q1 24 | $162.6M | — |
股东权益LCNBRXRX
| Q4 25 | $273.9M | $1.1B | ||
| Q3 25 | $269.9M | $1.0B | ||
| Q2 25 | $263.5M | $919.1M | ||
| Q1 25 | $258.7M | $933.9M | ||
| Q4 24 | $253.0M | $1.0B | ||
| Q3 24 | $253.2M | $524.6M | ||
| Q2 24 | $245.2M | $584.4M | ||
| Q1 24 | $233.7M | $401.2M |
总资产LCNBRXRX
| Q4 25 | $2.2B | $1.5B | ||
| Q3 25 | $2.2B | $1.4B | ||
| Q2 25 | $2.3B | $1.3B | ||
| Q1 25 | $2.3B | $1.3B | ||
| Q4 24 | $2.3B | $1.4B | ||
| Q3 24 | $2.3B | $726.5M | ||
| Q2 24 | $2.4B | $775.9M | ||
| Q1 24 | $2.3B | $557.8M |
负债/权益比LCNBRXRX
| Q4 25 | 0.38× | 0.01× | ||
| Q3 25 | 0.39× | 0.01× | ||
| Q2 25 | 0.40× | 0.02× | ||
| Q1 25 | 0.40× | 0.02× | ||
| Q4 24 | 0.61× | 0.02× | ||
| Q3 24 | 0.61× | 0.04× | ||
| Q2 24 | 0.66× | 0.04× | ||
| Q1 24 | 0.70× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $34.4M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $33.4M | $-47.3M |
| 自由现金流率自由现金流/营收 | 140.2% | -133.1% |
| 资本支出强度资本支出/营收 | 4.0% | 3.5% |
| 现金转化率经营现金流/净利润 | 6.08× | — |
| 过去12个月自由现金流最近4个季度 | $54.5M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流LCNBRXRX
| Q4 25 | $34.4M | $-46.1M | ||
| Q3 25 | $14.0M | $-117.4M | ||
| Q2 25 | $5.5M | $-76.4M | ||
| Q1 25 | $2.2M | $-132.0M | ||
| Q4 24 | $93.2M | $-115.4M | ||
| Q3 24 | $11.9M | $-59.2M | ||
| Q2 24 | $54.9M | $-82.2M | ||
| Q1 24 | $-11.9M | $-102.3M |
自由现金流LCNBRXRX
| Q4 25 | $33.4M | $-47.3M | ||
| Q3 25 | $13.7M | $-117.6M | ||
| Q2 25 | $5.2M | $-79.6M | ||
| Q1 25 | $2.1M | $-133.8M | ||
| Q4 24 | $89.4M | $-116.7M | ||
| Q3 24 | $10.5M | $-63.8M | ||
| Q2 24 | $53.8M | $-83.4M | ||
| Q1 24 | $-12.8M | $-109.0M |
自由现金流率LCNBRXRX
| Q4 25 | 140.2% | -133.1% | ||
| Q3 25 | 57.4% | -2272.5% | ||
| Q2 25 | 23.0% | -413.9% | ||
| Q1 25 | 10.0% | -907.4% | ||
| Q4 24 | 394.0% | -2567.7% | ||
| Q3 24 | 49.0% | -244.6% | ||
| Q2 24 | 278.6% | -578.5% | ||
| Q1 24 | -71.8% | -789.9% |
资本支出强度LCNBRXRX
| Q4 25 | 4.0% | 3.5% | ||
| Q3 25 | 1.3% | 4.7% | ||
| Q2 25 | 1.0% | 16.4% | ||
| Q1 25 | 0.3% | 12.4% | ||
| Q4 24 | 16.7% | 28.6% | ||
| Q3 24 | 6.7% | 17.5% | ||
| Q2 24 | 5.9% | 8.2% | ||
| Q1 24 | 4.8% | 48.2% |
现金转化率LCNBRXRX
| Q4 25 | 6.08× | — | ||
| Q3 25 | 2.02× | — | ||
| Q2 25 | 0.92× | — | ||
| Q1 25 | 0.48× | — | ||
| Q4 24 | 15.23× | — | ||
| Q3 24 | 2.63× | — | ||
| Q2 24 | 59.35× | — | ||
| Q1 24 | -6.24× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
